BD (Becton, Dickinson and Company) has announced the expansion of its respiratory and sexually transmitted infection (STI) diagnostics offerings in Europe following IVDR certification of two VIASURE assays developed by Certest Biotec for use on the BD MAX System.
The addition of these new assays to the BD MAX System portfolio enables clinical laboratories to detect a broad range of pathogens quickly and accurately using a fully automated molecular platform.
The newly certified assays include:
- VIASURE Respiratory Virus Extended Mix Real Time PCR Detection Kit:
Detects multiple respiratory viruses, including SARS-CoV-2, flu (A and B), RSV, parainfluenza, human coronavirus, metapneumovirus, and adenovirus, from a single nasopharyngeal swab
- VIASURE HSV-1, HSV-2 and Treponema pallidum assay:
Identifies the presence of herpes simplex viruses (HSV-1 and HSV-2) and the bacteria that causes syphilis (Treponema pallidum) using anogenital and oral skin lesion swabs.
"With these two assays, we are adding clinically relevant, targeted molecular panels to our already broad respiratory and STI menu," said Philippe Villiard, Vice President, BD Diagnostic Solutions in Europe. "Our partnership with Certest Biotec has been instrumental in expanding the BD MAX System menu and supports our commitment to delivering innovative diagnostic solutions that enable faster, more comprehensive detection of infectious diseases on the BD MAX System."
The BD MAX System can process up to 24 samples per run and offers a comprehensive assay menu spanning HAI, respiratory, enteric, STI and women's health panels, as well as offering open system capabilities. Designed for clinical laboratories and hospitals, the BD MAX System combines real-time PCR technology with automated nucleic acid extraction, amplification and detection in a single streamlined workflow. It delivers results in approximately three hours with less than one minute of hands-on time per sample, providing clinicians with timely, reliable information to support accurate treatment decisions and helping improve patient care.
"Our partnership with BD, which began in 2017, continues to grow and we are excited to strengthen our collaboration once again. We are confident that our joint efforts will result in exceptional projects in the future," affirmed Certest's CEO Nelson Fernandes.